<DOC>
	<DOCNO>NCT02902640</DOCNO>
	<brief_summary>This pilot , observational multicentric study safety sulfamethoxazole plus ( + ) trimethoprim + guaifenesin ( Balsamic Bactrim ) adult participant acute bronchitis . Overall , 50 adult participant acute bronchitis eligible treatment sulfamethoxazole + trimethoprim + guaifenesin enrol . Administration Balsamic Bactrim accord physician 's recommendation local labeling .</brief_summary>
	<brief_title>An Observational Study Assess Safety Sulfamethoxazole + Trimethoprim + Guaifenesin ( Balsamic Bactrim ) Adult Participants With Acute Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<criteria>Participants start treatment Balsamic Bactrim per treat physician 's discretion Participants clinical diagnosis acute bronchitis ( Cough without sputum production le 30 day ) Participants start treatment another antibiotic time visit Participants respiratory infection Participants mental disorder Participants severe hepatic parenchymal damage Participants severe renal failure drug plasma concentration monitor Participants hypersensitivity active ingredient excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>